# EDGAR Filing Document

**Accession Number:** 0001533743
**File Stem:** 0001493152-23-007564
**Filing Date:** 2023-3
**Character Count:** 6247
**Document Hash:** c016a129af33d36aecaa8bcbc81b9261
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-007564.hdr.sgml**: 20230314

**ACCESSION NUMBER**: 0001493152-23-007564

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 36

**CONFORMED PERIOD OF REPORT**: 20230314

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230314

**DATE AS OF CHANGE**: 20230314

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Processa Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001533743
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 451539785
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39531
- **FILM NUMBER:** 23729827

**BUSINESS ADDRESS:**
- **STREET 1:** 7380 COCA COLA DRIVE
- **STREET 2:** SUITE 106
- **CITY:** HANOVER
- **STATE:** MD
- **ZIP:** 21076
- **BUSINESS PHONE:** 443-776-3133

**MAIL ADDRESS:**
- **STREET 1:** 7380 COCA COLA DRIVE
- **STREET 2:** SUITE 106
- **CITY:** HANOVER
- **STATE:** MD
- **ZIP:** 21076

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Heatwurx, Inc.
- **DATE OF NAME CHANGE:** 20111028

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): March 14, 2023**

Commission file number 001-39531

**PROCESSA PHARMACEUTICALS, INC.**

**(Exact name of Registrant as Specified in its Charter)**

---

| | |
|:---|:---|
| **Delaware** | **45-1539785** |
| **(State or Other Jurisdiction of <br> Incorporation or Organization)** | **(I.R.S. Employer <br> Identification Number)** |

---

---

| |
|:---|
| **7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076** |
| **(Address of Principal Executive Offices, Including Zip Code)** |

---

---

| |
|:---|
| **(443) 776-3133** |
| **(Registrant's Telephone Number, Including Area Code)** |

---

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Common stock: Par value $.0001 | PCSA | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01. Regulation Disclosure.**

Processa Pharmaceuticals, Inc. ("***Processa***") will be virtually presenting at the Oppenheimer 33<sup>rd</sup> Annual Healthcare Conference at 12:00 PM Eastern on March 14, 2023. During these meetings, Processa's presentation will be uploaded into a portal, which is furnished as Exhibit 99.1 and is incorporated herein by reference. The presentation will also be made available in the "Investors" section on Processa's website, located at <u>https://www.processapharmaceuticals.com.</u>

Processa undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time through the filing of other reports or documents with the Securities Exchange Commission, through press releases, or through other public disclosure, including in the "Investors" section of Processa's website. Processa routinely uses its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit Description** |
| 99.1 | [Processa Pharmaceuticals Presentation dated March 14, 2023.](ex99-1.htm) |
| 104 | Cover Page Interactive Data File - The cover page XBRL tags are embedded within the inline XBRL document. |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on March 14, 2023.

---

| | |
|:---|:---|
| PROCESSA PHARMACEUTICALS, INC. | PROCESSA PHARMACEUTICALS, INC. |
| Registrant | Registrant |
| By: | */s/ David Young* |
|  | David Young |
|  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_1.jpg)

![](ex99-1_2.jpg)

![](ex99-1_3.jpg)

![](ex99-1_4.jpg)

![](ex99-1_5.jpg)

![](ex99-1_6.jpg)

![](ex99-1_7.jpg)

![](ex99-1_8.jpg)

![](ex99-1_9.jpg)

![](ex99-1_10.jpg)

![](ex99-1_11.jpg)

![](ex99-1_12.jpg)

![](ex99-1_13.jpg)

![](ex99-1_14.jpg)

![](ex99-1_15.jpg)

![](ex99-1_16.jpg)

![](ex99-1_17.jpg)

![](ex99-1_18.jpg)

![](ex99-1_19.jpg)

![](ex99-1_20.jpg)

![](ex99-1_21.jpg)

![](ex99-1_22.jpg)

![](ex99-1_23.jpg)